

Electronic Acknowledgement Receipt

EFS ID:	1115397
Application Number:	10625105
Confirmation Number:	8893
Title of Invention:	Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof
First Named Inventor:	Takashi Tsuji
Customer Number:	26161
Filer:	Jack Brennan/Susan Williams
Filer Authorized By:	Jack Brennan
Attorney Docket Number:	14539-006002
Receipt Date:	17-JUL-2006
Filing Date:	22-JUL-2003
Time Stamp:	16:05:05
Application Type:	Utility
International Application Number:	

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1		14539006002RES.pdf	889648	yes	25

	Multipart Description		
	Doc Desc	Start	End
	Amendment - After Non-Final Rejection	1	1
	Specification	2	2
	Claims	3	22
	Applicant Arguments/Remarks Made in an Amendment	23	25

Warnings:

Information:

Total Files Size (in bytes):	889648
------------------------------	--------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.